Neurology

One particularly important area where we are placing our Partnering efforts is in Neuroscience. We believe the field of Neurology is on the cusp of important breakthroughs in both early diagnosis and treatment. Our relentless pursuit of scientific innovation is taking us into areas of enormous unmet medical need and progress in treating diseases of the brain and nervous system.

Our collaborative efforts have resulted in one of the strongest and most diverse pipelines in the industry, spanning the spectrum of nervous system disorders from the rarest to the most common.

Partnering opportunities we are looking for:

• Neurodegenerative diseases (e.g. Alzheimer's disease, Parkinson's disease, Huntington disease)
• Neuroinflammation (e.g. Multiple sclerosis)
• Neuromuscular diseases (e.g. ALS, Duchenne Muscular Dystrophy)
• Transformational therapies in other CNS indications

Example partnerships

Atalanta Therapeutics – Collaboration entails the development of RNAi therapeutics for multiple CNS targets for neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease.

Inflazome – Acquisition of company including portfolio composed of clinical and preclinical orally available small molecule NLRP3 inhibitors for multiple indications including CNS

Ionis Pharmaceuticals - Early stage programs for RNA-targeting investigational medicines for the treatment of Alzheimer's disease (AD) and Huntington's disease (HD)

Sangamo Therapeutics - Exclusive license to Sangamo’s proprietary zinc finger repressors directed to the tau gene, which is critically involved in AD and other tauopathies, as well as an undisclosed second neurology target.

Your dedicated partnering leads in Neurology

Tom Zioncheck, Head of Neurology, Ophthalmology and Rare Diseases, Pharma Partnering

Rose Damestani, Search & Evaluation Lead Neurology, Ophthalmology & Rare Diseases, Pharma Partnering